Physician profile
Irene Yu
NPI 1063590826
$4,280.54
in general payments reported to CMS, 2019-2025
28 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $434 · 2021: $630 · 2022: $541 · 2023: $719 · 2024: $776 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $637.22 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $629.76 | 2021-2025 | |
| Glaxosmithkline, LLC. | $551.22 | 2019-2025 | Nucala |
| Optinose US, INC. | $335.05 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $318.37 | 2019 | |
| Kaleo, INC. | $242.42 | 2020-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $214.91 | 2020-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $162.78 | 2019-2023 | Fasenra |
| Innovation Technologies INC | $142.91 | 2021 | |
| Cook Medical LLC | $101.61 | 2022 | |
| Csl Behring | $100.63 | 2021-2025 | Hizentra |
| Genentech USA, INC. | $89.10 | 2024-2025 | Xolair |
| Greer Laboratories, INC. | $85.81 | 2019 | |
| Inspire Medical Systems, INC. | $84.46 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $84.17 | 2020-2024 | Cuvitru |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $69.83 | 2023-2024 | Ryaltris |
| Alk-Abello, INC | $67.37 | 2019 | |
| Incyte Corporation | $61.75 | 2021-2022 | |
| Grifols USA, LLC | $61.35 | 2023-2024 | Xembify |
| Teva Pharmaceuticals USA, INC. | $45.64 | 2020 | |
| Stryker Corporation | $37.18 | 2019 | |
| Merck Sharp & Dohme LLC | $33.15 | 2022-2023 | |
| Intersect Ent, INC. | $32.93 | 2019 | |
| Neurent Medical Limited | $23.46 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Medtronic, INC. | $22.57 | 2025 | Stealthstation S8 Platform |
| Smith+Nephew, INC. | $17.26 | 2020 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Phadia US INC. | $13.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.